Abstract
The problem of interpreting missense mutations of disease-causing genes is an increasingly important one. Because these point mutations result in alteration of only a single amino acid of the protein product, it is often unclear whether this change alone is sufficient to cause disease. We propose a Bayesian approach that utilizes genetic information on affected relatives in families ascertained through known missense-mutation carriers. This method is useful in evaluating known disease genes for common disease phenotypes, such as breast cancer or colorectal cancer. The posterior probability that a missense mutation is disease causing is conditioned on the relationship of the relatives to the proband, the population frequency of the mutation, and the phenocopy rate of the disease. The approach is demonstrated in two cancer data sets: BRCA1 R841W and APC I1307K. In both examples, this method helps establish that these mutations are likely to be disease causing, with Bayes factors in favor of causality of 5.09 and 66.97, respectively, and posterior probabilities of .836 and .985. We also develop a simple approximation for rare alleles and consider the case of unknown penetrance and allele frequency.
MeSH Terms
Adenomatous Polyposis Coli/epidemiology,genetics
Alleles
BRCA1 Protein/genetics
Breast Neoplasms/epidemiology,genetics
Female
Genes, Dominant
Heterozygote
Humans
Models, Genetic
Mutation
Penetrance
Prevalence
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Petersen G M
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA.
[email protected]
Parmigiani G
Thomas D
References (14)
14 references, click to expand
-
Effective testing of gene-disease associations.
Am J Hum Genet. 1990 Aug;47(2):266-74
PMID: 2378351
-
Methods for epidemiologic analyses of multiple exposures: a review and comparative study of maximum-likelihood, preliminary-testing, and empirical-Bayes regression.
Stat Med. 1993 Apr 30;12(8):717-36
PMID: 8516590
-
The genetics of breast and ovarian cancer.
Br J Cancer. 1995 Oct;72(4):805-12
PMID: 7547224
-
How is the Human Genome Project doing, and what have we learned so far?
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10841-8
PMID: 7479895
-
Pitfalls of genetic testing.
N Engl J Med. 1996 May 2;334(18):1192-4
PMID: 8602190
-
A gene map of the human genome.
Science. 1996 Oct 25;274(5287):540-6
PMID: 8849440
-
Predictive genetic testing: from basic research to clinical practice.
Science. 1997 Oct 24;278(5338):602-5
PMID: 9381169
-
Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer.
Cancer Genet Cytogenet. 1996 Dec;92(2):130-4
PMID: 8976369
-
Molecular genetic approaches to understanding disease.
BMJ. 1997 Jan 11;314(7074):126-9
PMID: 9006475
-
Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent.
JAMA. 1997 May 14;277(18):1467-74
PMID: 9145720
-
Hierarchical modeling of gene-environment interactions: estimating NAT2 genotype-specific dietary effects on adenomatous polyps.
Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):307-14
PMID: 9149889
-
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC.
Nat Genet. 1997 Sep;17(1):79-83
PMID: 9288102
-
Human cancer syndromes: clues to the origin and nature of cancer.
Science. 1997 Nov 7;278(5340):1043-50
PMID: 9353177
-
BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.
Genet Epidemiol. 1996;13(6):595-604
PMID: 8968716